2016 ANNUAL REPORT 2016 ANNUAL REPORT MEMORIAL SLOAN KETTERINGMEMORIAL CANCER SLOAN CENTER GENERAL INFORMATION 212.639.2000 1275 YORK AVENUE MAKE AN APPOINTMENT NEW YORK, NY 10065 800.525.2225 VISIT US ONLINE WWW.MSKCC.ORG FACEBOOK.COM/SLOANKETTERING TWITTER.COM/SLOAN_KETTERING YOUTUBE.COM/MSKCC INSTAGRAM.COM/SLOANKETTERING WWW.MSKCC.ORG/ANNUALREPORT 2016: A YEAR OF I N N O VAT I O N I N N O VAT I O N INNOVATION Cancer will never have a one-size-fits-all solution. This intricate, challenging, ever- shifting disease is nothing if not complex. And though it’s often described with a single word — cancer — there are actually more than 400 distinct types, each with its own unique characteristics and vulnerabilities. The doctors, nurses, and scientists at Memorial around the world. We unearthed new answers Sloan Kettering are experts at matching cancer’s to old questions about fundamental biological complexity with an equally nuanced understanding processes. We tested and perfected novel of all its varieties. We strive to choose the optimal technologies and brought them directly to treatment for every patient, and we’re always patients. We led the development of drugs searching for better ways to do so. for cancers that haven’t seen new therapies in decades — and brought them through to FDA We address cancer’s intricacy from every approval. And we opened new locations and possible angle, both by thinking creatively refreshed existing ones to better accommodate and by utilizing the latest, most pioneering the needs of our unique patients. advances in technology, basic and clinical research, treatment, and patient care. In this report, you’ll get to know some of the revolutionary thinkers and caring individuals In 2016, our scientists and clinicians made that make MSK a place like no other. And you’ll field-changing discoveries that will shape the see why 2016 was truly a study in innovation. future of treatment for people with cancer 2. MEMORIAL 2016 SLOAN KETTERING ANNUAL CANCER CENTER REPORT CONTENTS MESSAGE FROM THE CHAIRMAN AND THE PRESIDENT 4 INNOVATIONS IN: SCIENCE 8 INNOVATIONS IN: TREATMENT 24 INNOVATIONS IN: CLINICAL RESEARCH 38 INNOVATIONS IN: PATIENT CARE 48 STATISTICAL PROFILE 56 FINANCIAL SUMMARY 58 BOARDS OF OVERSEERS AND MANAGERS 60 LEADERSHIP 61 THE CAMPAIGN FOR MEMORIAL SLOAN KETTERING 63 DONORS TO THE CAMPAIGN FOR MEMORIAL SLOAN KETTERING 64 THE SOCIETY OF MEMORIAL SLOAN KETTERING CANCER CENTER 81 3. INNOVATION MESSAGE FROM THE CHAIRMAN AND THE PRESIDENT CRAIG B. THOMPSON DOUGLAS A. WARNER III PRESIDENT AND CHAIR, BOARDS OF OVERSEERS CHIEF EXECUTIVE OFFICER AND MANAGERS 4. MEMORIAL 2016 SLOAN KETTERING ANNUAL CANCER CENTER REPORT The nation focused on cancer research and treatment with renewed intensity in 2016 because of a confluence of important developments in the realms of policy and medicine. Vice President Joseph Biden, who lost a son to brain cancer, issued a call to action to scientists, clinicians, and the private sector, urging greater data sharing and collaboration. At the same time, researchers at Memorial Sloan Kettering and other National Cancer Institute–designated cancer centers demonstrated the power of genomics to identify effective treatments that will benefit more people with cancer. MSK hosted a roundtable conversation with Mr. Biden trials, according to a major study conducted this year that brought together leaders from a variety of areas on behalf of MSK. For example, too many physicians of cancer research and treatment, including our own still believe clinical trials are treatments of last resort. Carol Brown, a gynecologic surgeon and Director of the As a comprehensive cancer center, MSK can play an Office of Diversity Programs in Clinical Care, Research, important role in changing perceptions of clinical trials and Training. Mr. Biden’s Cancer Moonshot initiative and their value in advancing cancer care. helped galvanize Congress to pass the 21st Century Cures Act, which increased funding for the National There are numerous paths to achieving this goal. In Institutes of Health. The legislation enjoyed broad December 2016, we announced a partnership with support among both Republicans and Democrats. Hackensack Meridian Health, one of New Jersey’s largest and most respected healthcare systems. The The Cancer Moonshot initiative highlighted key partnership will enable greater access to clinical trials areas of particular importance: the need for greater for residents of New Jersey, with the goal of accelerating and more diverse participation in clinical research the development of new cures for cancer. At the and the importance of identifying ways to effectively same time, membership in the MSK Cancer Alliance manage the vast amount of data generated by genomic expanded to include the Miami Cancer Institute at sequencing. It also underscored the value of fundamental Baptist Health South Florida. Alliance members, research in the biological sciences in fields as diverse including the Hartford HealthCare Cancer Institute as nanotechnology, epigenetics, and molecular biology. in Connecticut and Lehigh Valley Health Network in These are all areas in which MSK excels. Indeed, the Pennsylvania, are able to offer MSK clinical trials to power of MSK’s collective research accomplishment their patients and participate in key clinical activities was noted last year when the Nature Publishing Group with MSK’s physicians and staff. once again ranked MSK first among all cancer centers in the world for high-quality research output in 2016. MSK continues to focus on how best to analyze the results of cancer DNA sequencing to improve cancer MSK remains committed to increasing patient access treatment and share that information with other health to promising new therapies through clinical trials. systems. MSK physician-scientist Charles Sawyers has Nationwide, members of the public and physicians still taken the lead in addressing this need. A past president harbor many misconceptions about cancer clinical of the American Association for Cancer Research 5. INNOVATION KATHRYN MARTIN JOSÉ BASELGA JOAN MASSAGUÉ JAMES D. ROBINSON III Chief Operating Physician-in-Chief and Director, Honorary Chair, Officer Chief Medical Officer, Sloan Kettering Boards of Overseers Memorial Hospital Institute and Managers (AACR), Dr. Sawyers collaborated with the AACR to help researchers unravel how various immune system create an initiative called Project GENIE (Genomics components interact. Evidence Neoplasia Information Exchange) that pulls together data from MSK and seven other leading cancer Our leadership in immunotherapy was further research institutions. The Project GENIE database solidified when we became one of six founding members already includes information on 59 major cancer types, of the Parker Institute for Cancer Immunotherapy with data from nearly 3,000 lung cancer patients, as (PICI), established by tech entrepreneur Sean Parker well as 2,000 patients with breast cancer and more in April 2016. It brings together 300 of the country’s than 2,000 patients with colorectal cancer. This unique leading immunologists, who are dedicated to a single effort enables investigators from around the world to mission: harnessing the power of the immune system ask — and answer — questions about the link between to fight cancer. The first findings from work jointly genes, treatments, and outcomes. conducted through PICI — which is co-directed at MSK by Jedd Wolchok, an expert on melanoma and MSK’s own genetic sequencing efforts hit a significant the immunotherapy approach known as checkpoint milestone in early 2017, when our researchers, led by blockade, and Marcel van den Brink, a specialist in Michael Berger and Ahmet Zehir, reported results blood cancer and bone marrow transplantation — are from the first 10,336 patients who had their tumors beginning to unfold. sequenced through MSK-IMPACT — a test created by our genome scientists, bioinformaticians, and molecular Ongoing investment in MSK’s physical infrastructure pathologists to detect genetic errors in both rare and remains critical to the success of both our scientific and common cancers. Nearly 37 percent of those patients clinical programs. This past year saw the addition of an had a potentially actionable mutation. Since hitting that important new research technology, an advanced cryo- landmark, the test has been used to sequence tumors in electron microscope. Located on the ground floor of the more than 16,000 patients, leading to greater insights Rockefeller Research Laboratories building, the Titan and treatment options for these individuals. Krios further strengthens SKI’s commitment to structural biology and the ability to better understand the structure Immunotherapy represents a substantial opportunity of key biological molecules involved in cancer. to both advance and personalize cancer treatment. Our scientists are generating unprecedented insights in On the clinical side, MSK has reimagined existing this field. In one recent example, Daniel Bachovchin, a space at Memorial Hospital to better meet the needs of chemical biologist in the Sloan Kettering Institute (SKI), neurosurgical and orthopedic patients while developing and colleagues discovered that the immunotherapy new space and programs within the regional care drug Val-boroPro activates the immune system to network. Particularly noteworthy is the December attack cancers through a form of highly inflammatory opening of MSK Monmouth in Middletown, New Jersey. programmed cell death called pyroptosis.